What is BioCardia?
BioCardia operates as a clinical-stage enterprise dedicated to the development of regenerative medicine solutions specifically engineered to treat cardiovascular diseases. The company's primary value proposition lies in its proprietary CardiAMP and CardiALLO platforms, which utilize intramyocardial delivery of marrow-derived cells to address complex cardiac pathologies. By focusing on comprehensive biotherapeutic solutions, BioCardia aims to redefine the standard of care for patients suffering from conditions that have historically lacked effective treatment options. The company's market position is bolstered by its commitment to rigorous clinical validation, ensuring that its therapeutic candidates meet the highest standards of efficacy and safety required for modern medical intervention.
How much funding has BioCardia raised?
BioCardia has raised a total of $8.8M across 2 funding rounds:
Debt
$4.4M
Stock/Share Issuance
$4.4M
Debt (2016): $4.4M, investors not publicly disclosed
Stock/Share Issuance (2026): $4.4M, investors not publicly disclosed
Key Investors in BioCardia
Undisclosed Investors
Undisclosed Investors
Undisclosed Investors
What's next for BioCardia?
With the recent capital injection, BioCardia is well-positioned to accelerate its clinical development programs and expand its operational capacity. The strategic focus will likely shift toward scaling the manufacturing processes for its cell-based therapies and finalizing the data sets required for potential regulatory submissions. As the company moves deeper into its clinical-stage lifecycle, the management team will prioritize the optimization of its intramyocardial delivery systems to enhance patient outcomes. Future growth will be contingent upon the successful execution of ongoing trials and the ability to navigate the complex regulatory environment governing regenerative medicine. Investors will be closely monitoring the progression of the CardiAMP and CardiALLO programs as they approach pivotal data readouts, which will serve as the primary indicators of the company's long-term commercial viability and potential for market disruption in the cardiovascular space.
See full BioCardia company page
